Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 17th 2014

Merck's Pembrolizumab: Breakthrough in NSCLC

Surabhi Dangi-Garimella, PhD

November 17th 2014

Panel Members Discuss Data Quality in Oncology Care

Surabhi Dangi-Garimella, PhD

November 17th 2014

The Challenge of Developing the Ideal Patient Satisfaction Survey

Betsy Chase Steven Dâ€™Amato, BSPharm, BCOP

November 17th 2014

The Debate on Treatment Options in Early-Stage Breast Cancer

Surabhi Dangi-Garimella, PhD

November 17th 2014

AJMC Oncology Conference Helps Managed Care Stakeholders Do More for Patients Who Have Coverage, But Still Have Limits

At its third annual conference, Patient-Centered Oncology Care 2014, The American Journal of Managed Care addressed new challenges in cancer care: more patients have coverage, but they may be "underinsured" or barred from academic centers. Amid rising drug costs and regulations that threaten community practices, the head of the largest oncology organization outlined a path toward value-based reimbursement.

November 17th 2014

Nivolumab Presents Superior Survival Results in Phase 3 Melanoma Trials

In a press release based off-of results presented at the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, BMS announced results from phase 3 of the CheckMate-066 trial.

November 16th 2014

A New Glioblastoma Vaccine on the Horizon

Following encouraging results from a second phase of a phase 1 trial, the researchers have planned a second phase, to be initiated in January 2015. The vaccine will be administered to glioblastoma patients just before they begin chemotherapy.

November 16th 2014

Long-term Results of Vismodegib in Patients With Basal Cell Carcinoma Reported

Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.

November 16th 2014

Oncolytic Virus Proves Promising in Advanced Melanoma

Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.

November 16th 2014

Vemurafenib Treatment Beyond Progression Is Safe and Highly Effective in Patients with Metastatic Melanoma

Patients with metastatic melanoma receiving vemurafenib following disease progression showed similar or better overall response to patients without progressive disease, according to findings from an analysis reported at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.

November 16th 2014

More Good News on Pembrolizumab for Melanoma Patients Without Other Options

Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.

November 15th 2014

More Details Presented on Melanoma Diagnostic Test

Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.

November 15th 2014

Autophagy Regulators: An Emerging Target in Melanoma

During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.

November 14th 2014

Integrating Palliative Care Into Managed Care for the Good of Patients

Mary K. Caffrey

Yesterday, speakers opened Patient-Centered Oncology Care, sponsored by The American Journal of Managed Care, with a discussion of how to bring palliative care into the mainstream in cancer care. While progress has been made, a cultural bias against discussion end-of-life issue remains an obstacle.

November 14th 2014

FDA Approves Avastin Plus Chemotherapy for Platinum-Resistant Ovarian Cancer

Genentech announced that Avastin has been approved to treated platinum-resistant ovarian cancer, inc combination with chemotherapy, which now expands Avastin's use to 6 tumor types.

November 14th 2014

Managed Care Audience Hears ASCO's Peter Yu, MD, Describe Value-Based Efforts

Mary K. Caffrey

Peter Yu, MD, president of the American Society of Clinical Oncology, (ASCO) discussed the organization's efforts throughout 2014 to reform reimbursement and take on issues of value and quality in cancer care during Patient-Centered Oncology Care, the annual gathering sponsored by The American Journal of Managed Care.

November 13th 2014

Smokers Know Tobacco Responsible for their Bladder Cancer, Study Discovers

A Kaiser Permanante study surveyed bladder cancer patients and found that current and former smokers were aware of a connection between smoking and their disease.

November 13th 2014

NICE Comes Back With a List of 40 Expensive Drugs to Be Reassessed

The cost-value discussion in oncology continues in Europe as NICE lists 40 drugs that it plans to reassess in terms of cost versus patient benefit.

November 13th 2014

Repeat Breast Surgeries an Unnecessary Burden on Patients, Survey Finds

A national survey published in JAMA Surgery identified too many repeat surgeries in women with breast cancer.

November 12th 2014

Study Points to Disparity in HPV Vaccine Uptake

At an ongoing AACR meeting on Health Disparities in cancer, researchers from the Gillings School of Global Public Health presented data showing HPV vaccine uptake among girls is lowest in states with the highest rates of cervical cancer.

November 12th 2014

SIGO Releases New Guildelines for CRC in Older Patients

The recommendations by the International Society of Geriatric Oncology, emphasize personalized treatment and assigning a multidisciplinary care team for optimal treatment.

November 12th 2014

Scientists Discover New Prognostic Markers For Ovarian Cancer

A research group at the Roswell Park Cancer Institute employed 2 different approaches on data generated by The Cancer Genome Atlas, to identify prognostic genes in ovarian cancer.

November 11th 2014

Targeting ALK Mutations In Children With Neuroblastoma

A collaboration between CHOP oncologists and researchers at UPenn aims to provide targeted therapy to children with neuroblastoma, based on their ALK mutation status.

November 11th 2014

Cardiologists Draw Attention to Cardiac Side Effects of Oncology Regimens

At the annual meeting of the Heart Failure Society of America, cardiologists called for a more broader definition of cancer treatment—related cardiotoxicity.

November 11th 2014

Fast-Track for Thershold Pharma's Soft Tissue Sarcoma Drug

A Phase 3 trial for the drug, TH-302, is currently ongoing.

November 10th 2014

Medicare Says "Yes" to LDCT in Lung Cancer

CMS announced today that low-dose computed tomography screening will now be reimbursed once a year by Medicare as a preventive service benefit, despite an advisory panel recommending against the screening back in April 2014.

November 10th 2014

Issues With Provenge Come Back and Haunt Dendreon-Files for Chapter 11

Provenge, approved by the FDA in 2010, faced numerous road-blocks with high cost, limited benefit, and issues with reimbursement rates.

November 9th 2014

Panobinostat Hears a

The FDA Oncologic Drugs Advisory Committee voted against recommending panobinostat plus bortezomib and dexamethasone for patients with previously treated multiple myeloma.

November 8th 2014

First Case of Successful Personalized Treatment in Liver Cancer Reported

The treatment, conducted at the University of Pennsylvania, identified a mutation in the BRaf gene which is commonly mutated in melanoma. Subsequent treatment with dabrafenib and trametinib resulted in rapid tumor shrinkage.

November 7th 2014

NEJM Study Could Influence Medicare Coverage of CT Screening in Lung Cancer

The study results from the National Lung Screening Trial found cost-effectiveness and value of screening long-term smokers when screened by trained professionals.

...

145 146 147 148 149 150 151 152 153

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions